Gena Wang
Stock Analyst at Barclays
(2.15)
# 2,743
Out of 4,734 analysts
191
Total ratings
36.72%
Success rate
-3.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLUE bluebird bio | Maintains: Overweight | $2 → $40 | $8.35 | +379.04% | 10 | Dec 31, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $509 → $418 | $422.00 | -0.95% | 15 | Dec 20, 2024 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $5 → $3 | $1.22 | +145.90% | 9 | Dec 13, 2024 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $45 → $56 | $43.84 | +27.74% | 14 | Dec 3, 2024 | |
| KOD Kodiak Sciences | Maintains: Underweight | $3 → $4 | $7.17 | -44.21% | 8 | Nov 15, 2024 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $3 → $9 | $1.09 | +725.69% | 3 | Nov 14, 2024 | |
| MRNA Moderna | Maintains: Overweight | $125 → $111 | $34.06 | +225.90% | 7 | Nov 8, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $76 → $55 | $9.50 | +478.95% | 6 | Nov 8, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $59 → $55 | $40.53 | +35.70% | 14 | Nov 6, 2024 | |
| CLLS Cellectis | Maintains: Overweight | $7 → $5 | $1.48 | +237.84% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $8 | $7.45 | +7.38% | 9 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $10.11 | +157.17% | 5 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $329 | $246.27 | +33.59% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $61.53 | +39.77% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $63 | $28.92 | +117.84% | 1 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $15 | $3.27 | +358.72% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $226 → $203 | $118.00 | +72.03% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $33 → $31 | $23.44 | +32.25% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $7.37 | +578.43% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $40.00 | +102.50% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $51 | $31.43 | +62.27% | 9 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $4.58 | +882.53% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $32.66 | +187.81% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $13.88 | -35.16% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $16.79 | +48.90% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $6.26 | +187.54% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $8 | $6.87 | +16.45% | 1 | Nov 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $2.97 | +203.03% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.22 | +5,168.20% | 1 | Jan 6, 2017 |
bluebird bio
Dec 31, 2024
Maintains: Overweight
Price Target: $2 → $40
Current: $8.35
Upside: +379.04%
Vertex Pharmaceuticals
Dec 20, 2024
Maintains: Equal-Weight
Price Target: $509 → $418
Current: $422.00
Upside: -0.95%
Editas Medicine
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $1.22
Upside: +145.90%
PTC Therapeutics
Dec 3, 2024
Maintains: Equal-Weight
Price Target: $45 → $56
Current: $43.84
Upside: +27.74%
Kodiak Sciences
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $7.17
Upside: -44.21%
Sangamo Therapeutics
Nov 14, 2024
Maintains: Overweight
Price Target: $3 → $9
Current: $1.09
Upside: +725.69%
Moderna
Nov 8, 2024
Maintains: Overweight
Price Target: $125 → $111
Current: $34.06
Upside: +225.90%
Intellia Therapeutics
Nov 8, 2024
Maintains: Overweight
Price Target: $76 → $55
Current: $9.50
Upside: +478.95%
CRISPR Therapeutics AG
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $59 → $55
Current: $40.53
Upside: +35.70%
Cellectis
Nov 5, 2024
Maintains: Overweight
Price Target: $7 → $5
Current: $1.48
Upside: +237.84%
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $7 → $8
Current: $7.45
Upside: +7.38%
Nov 4, 2024
Maintains: Overweight
Price Target: $28 → $26
Current: $10.11
Upside: +157.17%
Nov 1, 2024
Maintains: Overweight
Price Target: $295 → $329
Current: $246.27
Upside: +33.59%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $61.53
Upside: +39.77%
Aug 28, 2024
Initiates: Overweight
Price Target: $63
Current: $28.92
Upside: +117.84%
Aug 14, 2024
Maintains: Overweight
Price Target: $18 → $15
Current: $3.27
Upside: +358.72%
Aug 8, 2024
Maintains: Overweight
Price Target: $226 → $203
Current: $118.00
Upside: +72.03%
Aug 7, 2024
Maintains: Equal-Weight
Price Target: $33 → $31
Current: $23.44
Upside: +32.25%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $7.37
Upside: +578.43%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $40.00
Upside: +102.50%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $45 → $51
Current: $31.43
Upside: +62.27%
Apr 15, 2024
Initiates: Overweight
Price Target: $45
Current: $4.58
Upside: +882.53%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $32.66
Upside: +187.81%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $13.88
Upside: -35.16%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $16.79
Upside: +48.90%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $6.26
Upside: +187.54%
Nov 17, 2021
Maintains: Overweight
Price Target: $24 → $8
Current: $6.87
Upside: +16.45%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $2.97
Upside: +203.03%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.22
Upside: +5,168.20%